about
Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitorsThe skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis.The Proportion of Regulatory T Cells in Patients with Rheumatoid Arthritis: A Meta-AnalysisDNA damage in rheumatoid arthritis: an age-dependent increase in the lipid peroxidation-derived DNA adduct, heptanone-etheno-2'-deoxycytidine.Semaphorin 4D Contributes to Rheumatoid Arthritis by Inducing Inflammatory Cytokine Production: Pathogenic and Therapeutic Implications.A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade.Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein.A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Resu[Successful therapy with steroid and cyclophosphamide pulse for CNS lupus and lupus myelitis].Successful treatment of a patient with febrile, lobular panniculitis (Weber-Christian disease) with oral cyclosporin A: implications for pathogenesis and therapy.Adenovirus vector-based purging of multiple myeloma cells.MDM2 protein overexpression inhibits apoptosis of TF-1 granulocyte-macrophage colony-stimulating factor-dependent acute myeloblastic leukemia cells.p16INK4A promotes differentiation and inhibits apoptosis of JKB acute lymphoblastic leukemia cells.Pathological role of interleukin-6 in psoriatic arthritis.A point mutation in Semaphorin 4A associates with defective endosomal sorting and causes retinal degeneration.Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone.Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab.Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis.The molecular mechanism in activation-induced cell death of an Ag-reactive B cell clone.Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway.Levels of vascular endothelial growth factor and hepatocyte growth factor in sera of patients with rheumatic diseases.Quantification of hardness, elasticity and viscosity of the skin of patients with systemic sclerosis using a novel sensing device (Vesmeter): a proposal for a new outcome measurement procedure.Minimal neonatal transfer of certolizumab pegol in a Japanese patient with rheumatoid arthritis.The role of donor T cells for target organ injuries in acute and chronic graft-versus-host disease.Amelioration of small bowel injury by switching from nonselective nonsteroidal anti-inflammatory drugs to celecoxib in rheumatoid arthritis patients: a pilot study.A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.IgD multiple myeloma preceding the development of extensive extramedullary disease without medullary involvement.Increased serum interleukin-18 in a patient with systemic lupus erythematosus and T-cell large granular lymphocytic leukemia.346 Clinical Effects of Tocilizumab, a Humanized Anti-interleukin-6 Receptor Antibody, on Patients with Autoimmune and Allergic Diseases.Long-Term Safety and Efficacy of Weekly Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to Subcutaneous Tocilizumab Every Other Week: Results From the Open-Label Extension of the SHINOBI StudyInterleukin-6 as a new indicator of inflammatory status: detection of serum levels of interleukin-6 and C-reactive protein after surgeryInterleukin 6 levels in bile following liver transplantationAnti-interleukin-6 autoantibodies in rheumatic diseases. Increased frequency in the sera of patients with systemic sclerosisInterleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells[Interleukin-6]Serum interleukin 6 as a predicator of the therapeutic effect and adverse reactions after transcatheter arterial embolizationGp130 in human myeloma/plasmacytomaSystemic production of interleukin-6 following acute inflammation
P50
Q26824970-5DBA0AB7-DC13-4FC8-864A-9827D1A072FFQ34310749-E94BFBD2-C279-4D10-B269-C2329D25123EQ34477442-FED8B5D4-3140-403D-8202-59C7D16CCF0CQ36131101-0961486A-C6BE-4536-8538-057B824FABE1Q37270303-6EF24F0E-9365-4D49-B062-6797C280A749Q37275562-29F37DA8-A672-49F3-90F1-DEDAFBFA7484Q38193230-A19F9C67-ABC3-451F-BDC4-4D187EA4AF60Q38343244-60D5AD58-1764-4048-90D1-2DD3A352019AQ38353073-69D35324-4917-45FE-A42E-86BEF851BD84Q40169728-D0E67196-1EA7-46A6-8EA5-7D4CCE8E6FD6Q40435168-729BE54E-296A-41D8-82CA-920B3BEB18A0Q40634920-70C33592-08A1-494D-9E1B-DBE18A0AB776Q40989609-657BFCB6-5ECF-4FA0-AA27-A9EA57822E8CQ41021789-54D2400E-A12A-4208-9B2A-814706DDA336Q41081856-B20A2444-B3F2-42B2-B7B3-689356946121Q41589635-300DBD12-8E69-4207-A4EA-C06436ACB8A9Q41848410-3A6C71EF-AF27-42ED-BD8C-7063E7B4A293Q42536250-5B778FD9-B9C5-4856-8321-EF0C4DAAB472Q43233229-AF3D4AAC-C498-4B6A-A78D-08203BEF6322Q43444262-4B4D54FF-607C-472C-AEB5-3215C294B902Q44029844-0C74D7DD-182D-4219-959D-8BC1C4BD8F25Q45944887-D4B1AA57-E13D-4C0F-8416-1EC0DC07F022Q47702562-B1B4D2AA-DD4B-407E-A706-C071FCCA5B3CQ47745625-E9D049DF-B3EB-45E3-AD90-BD2487E0FB86Q47765008-FFB987A8-21FE-4397-8C0D-6C56B9CB032FQ49213075-B49E466C-1D29-4722-9ED1-4171D3676E4AQ50479209-09AC0E9D-5D4F-494F-9018-4886D9F73E30Q51439320-83A89FA7-BA04-42D9-B5FE-35234893879CQ53403438-4560B589-5C10-4E57-9A47-DE7CF0482983Q53584826-E6F7988E-3BD0-4C87-807A-A6D256434017Q55604446-162CBC83-DAFE-4784-B9A3-97EBFA37F8EFQ57291343-DFBFB394-199B-4DE1-9EA2-BCDD6B76D427Q67746128-547819E3-883B-4A9F-B023-7F9719B9A668Q68188297-05C3574E-E61C-4AFA-8046-28C26B233E85Q68232147-83E5E06E-77B7-4406-BCBD-F930BB214D46Q71933647-DB11E24F-BB46-4A62-8144-CE138D561B71Q72128529-CAC7ACB1-D752-404E-A6D3-35AEB7F8AC8BQ72309969-2252F82B-3566-4F6A-9428-B022E43C11D0Q72642602-DFC8A2B7-9EA7-4180-8331-B5DF0A068EDDQ72704154-855A8690-D256-41B8-93FF-B4A05B2BCFBF
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Atsushi Ogata
@ast
Atsushi Ogata
@en
Atsushi Ogata
@es
Atsushi Ogata
@nl
Atsushi Ogata
@sl
type
label
Atsushi Ogata
@ast
Atsushi Ogata
@en
Atsushi Ogata
@es
Atsushi Ogata
@nl
Atsushi Ogata
@sl
prefLabel
Atsushi Ogata
@ast
Atsushi Ogata
@en
Atsushi Ogata
@es
Atsushi Ogata
@nl
Atsushi Ogata
@sl
P106
P21
P31
P496
0000-0003-3944-3442
P569
2000-01-01T00:00:00Z